In Vitro Evaluation of Doxorubicin-Incorporated Magnetic Albumin Nanospheres
| dc.contributor.author | Zeybek, Ayça | |
| dc.contributor.author | Şanlı Mohamed, Gülşah | |
| dc.contributor.author | Ak, Güliz | |
| dc.contributor.author | Yılmaz, Habibe | |
| dc.contributor.author | Şanlıer, Şenay H. | |
| dc.coverage.doi | 10.1111/cbdd.12300 | |
| dc.date.accessioned | 2017-05-29T13:09:14Z | |
| dc.date.available | 2017-05-29T13:09:14Z | |
| dc.date.issued | 2014 | |
| dc.description.abstract | Magnetic albumin nanospheres that incorporate doxorubicin (M-DOX-BSA-NPs) were prepared previously by our research group to develop magnetically responsive drug carrier system. This nanocarrier was synthesized as a drug delivery system for targeted chemotherapy. In this work, cytotoxic effects of doxorubicin (DOX)-loaded/unloaded or magnetic/non-magnetic nanoparticles and free DOX against PC-3 cells and A549 cells were determined with the MTT test and the results were compared with each other. DOX-loaded magnetic albumin nanospheres (M-DOX-BSA-NPs) were found more cytotoxic than other formulations. The quantitative data obtained from flow cytometry analysis further verified the higher targeting and killing ability of M-DOX-BSA-NPs than free DOX on both of the cancer cell lines. Additionally, the results of cell cycle analysis have showed that M-DOX-BSA-NPs affected G1 and G2 phases. Finally, cell images were obtained using spin-disk confocal microscopy, and cellular uptake of M-DOX-BSA-NPs was visualized. The findings of this study suggest that M-DOX-BSA-NPs represent a potential doxorubicin delivery system for targeted drug transport into prostate and lung cancer cells. In this study, we found that M-DOX-BSA-NPs provide many advantages as targeted drug delivery, enhanced drug killing ability and bioavailability based on cytotoxicity, flow cytometry, and confocal microscopy image results. | en_US |
| dc.identifier.citation | Zeybek, A., Şanlı Mohamed, G., Ak, G., Yılmaz, H., and Şanlıer, Ş.H. (2014). In vitro evaluation of doxorubicin-incorporated magnetic albumin nanospheres. Chemical Biology and Drug Design, 84(1), 108-115. doi:10.1111/cbdd.12300 | en_US |
| dc.identifier.doi | 10.1111/cbdd.12300 | en_US |
| dc.identifier.doi | 10.1111/cbdd.12300 | |
| dc.identifier.issn | 1747-0277 | |
| dc.identifier.issn | 1747-0277 | |
| dc.identifier.issn | 1747-0285 | |
| dc.identifier.scopus | 2-s2.0-84902684883 | |
| dc.identifier.uri | https://doi.org/10.1111/cbdd.12300 | |
| dc.identifier.uri | https://hdl.handle.net/11147/5634 | |
| dc.language.iso | en | en_US |
| dc.publisher | John Wiley and Sons Inc. | en_US |
| dc.relation.ispartof | Chemical Biology and Drug Design | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | A549 cell line | en_US |
| dc.subject | Apoptosis | en_US |
| dc.subject | Doxorubicin | en_US |
| dc.subject | Magnetic albumin nanoparticle | en_US |
| dc.subject | Targeted drug delivery | en_US |
| dc.title | In Vitro Evaluation of Doxorubicin-Incorporated Magnetic Albumin Nanospheres | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | Zeybek, Ayça | |
| gdc.author.institutional | Şanlı Mohamed, Gülşah | |
| gdc.author.yokid | 115002 | |
| gdc.bip.impulseclass | C4 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C4 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Chemistry | en_US |
| gdc.description.endpage | 115 | en_US |
| gdc.description.issue | 1 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q3 | |
| gdc.description.startpage | 108 | en_US |
| gdc.description.volume | 84 | en_US |
| gdc.description.wosquality | Q2 | |
| gdc.identifier.openalex | W1970807752 | |
| gdc.identifier.pmid | 24524300 | |
| gdc.identifier.wos | WOS:000337665900011 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | BRONZE | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 7.0 | |
| gdc.oaire.influence | 3.0586211E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Magnetic albumin nanoparticle | |
| gdc.oaire.keywords | Cell Survival | |
| gdc.oaire.keywords | Apoptosis | |
| gdc.oaire.keywords | doxorubicin | |
| gdc.oaire.keywords | targeted drug delivery | |
| gdc.oaire.keywords | PC3 cell line | |
| gdc.oaire.keywords | A549 cell line | |
| gdc.oaire.keywords | Cell Line, Tumor | |
| gdc.oaire.keywords | Neoplasms | |
| gdc.oaire.keywords | magnetic albumin nanopArticle | |
| gdc.oaire.keywords | Animals | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Targeted drug delivery | |
| gdc.oaire.keywords | Drug Carriers | |
| gdc.oaire.keywords | Antibiotics, Antineoplastic | |
| gdc.oaire.keywords | Magnetic Phenomena | |
| gdc.oaire.keywords | Cell Cycle | |
| gdc.oaire.keywords | apoptosis | |
| gdc.oaire.keywords | Serum Albumin, Bovine | |
| gdc.oaire.keywords | Doxorubicin | |
| gdc.oaire.keywords | Magnets | |
| gdc.oaire.keywords | Cattle | |
| gdc.oaire.keywords | Nanospheres | |
| gdc.oaire.popularity | 4.9452735E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 0301 basic medicine | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 0.83288271 | |
| gdc.openalex.normalizedpercentile | 0.72 | |
| gdc.opencitations.count | 14 | |
| gdc.plumx.crossrefcites | 11 | |
| gdc.plumx.mendeley | 13 | |
| gdc.plumx.pubmedcites | 3 | |
| gdc.plumx.scopuscites | 15 | |
| gdc.scopus.citedcount | 15 | |
| gdc.wos.citedcount | 13 | |
| relation.isAuthorOfPublication.latestForDiscovery | eae23f7d-4b68-4072-9e21-c5a4a8c41aa3 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4011-8abe-a4dfe192da5e |
